Airsculpt Technologies, Inc. (AIRS)

In the past six months, AirSculpt Technologies' stock (AIRS) reached a new 52-week high of $12.00 on October 28, 2025, and has seen a significant increase of +542.3%. Key financial updates include the Q2 2025 earnings report on August 1, 2025, where the company reported a revenue of $39.54 million and earnings per share (EPS) of $0.14. Other events include a share offering in June 2025, which aimed to reduce debt by $16 million. Analyst ratings have generally been cautious, with a consensus rating of "Reduce" and an average price target of $3.75 from three analysts.

AirSculpt Technologies operates in the consumer-discretionary sector, making its demand susceptible to economic and market risks, as well as consumer spending hesitancy. Management has described consumer behavior as "choppy" and tentative, directly impacting case volume. While seasonality is a factor analyzed by the company, specific detailed patterns of peak and low demand periods for AirSculpt's body contouring services are not explicitly provided in the available information.

AirSculpt Technologies, Inc. is a holding company for EBS Intermediate Parent LLC, providing body contouring procedure services within the Healthcare sector, specifically in Medical Care Facilities. The company's core offering is AirSculpt, a minimally invasive body contouring treatment that removes fat and tightens skin. Other major products and procedures include AirSculpt+, AirSculpt Smooth, and various fat removal procedures across areas like the stomach, back, and buttocks. AirSculpt also provides fat transfer procedures to enhance areas such as the buttocks, breasts, hips, and aging hands.

AirSculpt Technologies operates a network of centers across the United States, Canada, and the United Kingdom. As of December 2024, the company had increased its clinic count to 32 locations. Recent expansions and relocations include new or redesigned offices in Atlanta (April 2024), Scottsdale (March 2024), Birmingham, MI, and White Plains, NY (December 2024).

AirSculpt Technologies maintains a generally positive brand reputation, highlighted by patient experiences and celebrity endorsements. News sentiment regarding AirSculpt Technologies has been neutral, with an even split of bullish and bearish news. No significant negative reputation events in the past year were identified in the search results.

The ownership structure of AirSculpt Technologies (AIRS) is primarily held by institutional investors and insiders. Institutional investors collectively own 91.54% of the company's stock. Major individual owners include Adam T. Feinstein, who holds 30.32 million shares, representing 48.57% of the company, and Aaron Rollins, the founder and executive chairman, who owns 15.15 million shares, accounting for 24.26%. Insiders collectively own 76.62% of the stock. Retail investors hold approximately 19.17% of the stock.